Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA-C Delivered in Fructose-Coated Micelles
- Publisher:
- WILEY-V C H VERLAG GMBH
- Publication Type:
- Journal Article
- Citation:
- Macromolecular Bioscience, 2017, 17, (10), pp. 1600513-n/a
- Issue Date:
- 2017
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
Macromolecular Bioscience - 2017 - Lu - Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA‐C Delivered.pdf | Published version | 1.18 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Lu, M | |
dc.contributor.author | Chen, F | |
dc.contributor.author | Noy, J-M | |
dc.contributor.author |
Lu, H https://orcid.org/0000-0001-6932-1900 |
|
dc.contributor.author | Stenzel, MH | |
dc.date.accessioned | 2022-10-03T20:51:18Z | |
dc.date.available | 2022-10-03T20:51:18Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Macromolecular Bioscience, 2017, 17, (10), pp. 1600513-n/a | |
dc.identifier.issn | 1616-5195 | |
dc.identifier.issn | 1616-5195 | |
dc.identifier.uri | http://hdl.handle.net/10453/162246 | |
dc.description.abstract | The ruthenium complex-dichlororuthenium (II) (p-cymene) (1,3,5-triaza-7-phosphaadamantane) (RAPTA-C)-has shown to be remarkably effective at suppressing the growth of solid tumor metastases. However, poor delivery efficacy and the lack of targeting ability of the common drug delivery system pose significant obstacles to maximize the therapeutic benefit of RAPTA-C. Inspired by the overexpression of GLUT5 transporter on the surface of breast cancer tissues but not the healthy mammary tissues, the use of d-fructose as the targeting moiety of the drug carrier can significantly improve the cellular uptake of nanoparticles, thus further enhancing the therapeutic efficiency of RAPTA-C. In this work, fructose-micelles and 2-hydroxyethyl acrylate (HEA)-micelles are prepared to investigate the difference in cellular uptake. It is found that glycopolymer leads to an increased uptake by breast cancer cells, while the HEA-micelles show less uptake. This behavior is also reflected by the slightly faster movement of fructose-coated micelles in MCF-7 tumor spheroid models using light sheet microscopy as analytical tool. The incorporation of RAPTA-C into micelles can enhance the inhibitory effect of the ruthenium drug demonstrated using invasion, chemotaxis, and haptotaxis assays. As a result, fructose-coated nanoparticles can be a promising drug delivery platform of RAPTA-C for the treatment of metastatic breast cancer. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | WILEY-V C H VERLAG GMBH | |
dc.relation.ispartof | Macromolecular Bioscience | |
dc.relation.isbasedon | 10.1002/mabi.201600513 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 0303 Macromolecular and Materials Chemistry, 0903 Biomedical Engineering, 0904 Chemical Engineering | |
dc.subject.classification | Polymers | |
dc.subject.mesh | Acrylates | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Cell Line, Tumor | |
dc.subject.mesh | Cell Movement | |
dc.subject.mesh | Cymenes | |
dc.subject.mesh | Drug Carriers | |
dc.subject.mesh | Drug Compounding | |
dc.subject.mesh | Female | |
dc.subject.mesh | Fructose | |
dc.subject.mesh | Gene Expression | |
dc.subject.mesh | Glucose Transporter Type 5 | |
dc.subject.mesh | Humans | |
dc.subject.mesh | MCF-7 Cells | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Micelles | |
dc.subject.mesh | Molecular Targeted Therapy | |
dc.subject.mesh | Neoplasm Proteins | |
dc.subject.mesh | Organometallic Compounds | |
dc.subject.mesh | RAW 264.7 Cells | |
dc.subject.mesh | Spheroids, Cellular | |
dc.subject.mesh | Cell Line, Tumor | |
dc.subject.mesh | Spheroids, Cellular | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Acrylates | |
dc.subject.mesh | Organometallic Compounds | |
dc.subject.mesh | Fructose | |
dc.subject.mesh | Neoplasm Proteins | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Drug Carriers | |
dc.subject.mesh | Drug Compounding | |
dc.subject.mesh | Cell Movement | |
dc.subject.mesh | Gene Expression | |
dc.subject.mesh | Micelles | |
dc.subject.mesh | Female | |
dc.subject.mesh | Glucose Transporter Type 5 | |
dc.subject.mesh | Molecular Targeted Therapy | |
dc.subject.mesh | MCF-7 Cells | |
dc.subject.mesh | RAW 264.7 Cells | |
dc.subject.mesh | Cymenes | |
dc.title | Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA-C Delivered in Fructose-Coated Micelles | |
dc.type | Journal Article | |
utslib.citation.volume | 17 | |
utslib.location.activity | Germany | |
utslib.for | 0303 Macromolecular and Materials Chemistry | |
utslib.for | 0903 Biomedical Engineering | |
utslib.for | 0904 Chemical Engineering | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | /University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2022-10-03T20:51:16Z | |
pubs.issue | 10 | |
pubs.publication-status | Published | |
pubs.volume | 17 | |
utslib.citation.issue | 10 |
Abstract:
The ruthenium complex-dichlororuthenium (II) (p-cymene) (1,3,5-triaza-7-phosphaadamantane) (RAPTA-C)-has shown to be remarkably effective at suppressing the growth of solid tumor metastases. However, poor delivery efficacy and the lack of targeting ability of the common drug delivery system pose significant obstacles to maximize the therapeutic benefit of RAPTA-C. Inspired by the overexpression of GLUT5 transporter on the surface of breast cancer tissues but not the healthy mammary tissues, the use of d-fructose as the targeting moiety of the drug carrier can significantly improve the cellular uptake of nanoparticles, thus further enhancing the therapeutic efficiency of RAPTA-C. In this work, fructose-micelles and 2-hydroxyethyl acrylate (HEA)-micelles are prepared to investigate the difference in cellular uptake. It is found that glycopolymer leads to an increased uptake by breast cancer cells, while the HEA-micelles show less uptake. This behavior is also reflected by the slightly faster movement of fructose-coated micelles in MCF-7 tumor spheroid models using light sheet microscopy as analytical tool. The incorporation of RAPTA-C into micelles can enhance the inhibitory effect of the ruthenium drug demonstrated using invasion, chemotaxis, and haptotaxis assays. As a result, fructose-coated nanoparticles can be a promising drug delivery platform of RAPTA-C for the treatment of metastatic breast cancer.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph